Synonym
Pirinixil; CCRIS134; CCRIS-134; CCRIS 134; BR931; BR 931; BR-931
IUPAC/Chemical Name
2-((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)-N-(2-hydroxyethyl)acetamide
InChi Key
RZCKTPORLKUFGY-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H19ClN4O2S/c1-10-4-3-5-12(11(10)2)19-14-8-13(17)20-16(21-14)24-9-15(23)18-6-7-22/h3-5,8,22H,6-7,9H2,1-2H3,(H,18,23)(H,19,20,21)
SMILES Code
O=C(NCCO)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
366.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: D'Atri G, Gomarasca P, Galimberti E, Sirtori CR, Kritchevsky D. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague- Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83. doi: 10.1016/0021-9150(80)90154-9. PMID: 7458993.
2: Kritchevsky D, Singer D, Klurfeld DM. Influence of hypocholesterolemic drugs on aortic cholesterol esterase in rabbits. Pharmacol Res Commun. 1984 Jun;16(6):525-31. doi: 10.1016/s0031-6989(84)80033-8. PMID: 6463093.
3: Lovati MR, De Marchi G. Plasma lipoprotein composition in cholesterol fed rabbits treated with pirinixil (BR 931), a new lipid lowering agent. Pharmacol Res Commun. 1981 Feb;13(2):133-9. doi: 10.1016/s0031-6989(81)80014-8. PMID: 7220573.
4: Najemnik C, Irsigler K, Sirtori CR. Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemias. Pharmacol Res Commun. 1981 Sep;13(8):777-86. doi: 10.1016/s0031-6989(81)80096-3. PMID: 7027276.
5: Kritchevsky D, Klurfeld DM, Tepper SA, Mueller MA, Puglisi L, Sirtori CR. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil (BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82. doi: 10.1016/s0031-6989(79)80019-3. PMID: 504321.
6: Simbula G, Pibiri M, Sanna L, Cossu C, Molotzu F, Columbano A, Ledda- Columbano GM. The peroxisome proliferator BR931 kills FaO cells by p53-dependent apoptosis. Life Sci. 2004 Jun 4;75(3):271-86. doi: 10.1016/j.lfs.2003.10.039. PMID: 15135649.
7: Shinozuka H, Abanobi SE, Lombardi B. Modulation of tumor promotion in liver carcinogenesis. Environ Health Perspect. 1983 Apr;50:163-8. doi: 10.1289/ehp.8350163. PMID: 6135607; PMCID: PMC1569229.
8: Eagon PK, Teepe AG, Elm MS, Tadic SD, Epley MJ, Beiler BE, Shinozuka H, Rao KN. Hepatic hyperplasia and cancer in rats: alterations in copper metabolism. Carcinogenesis. 1999 Jun;20(6):1091-6. doi: 10.1093/carcin/20.6.1091. PMID: 10357793.
9: Gupta C, Hattori A, Shinozuka H. Suppression of EGF binding in rat liver by the hypolipidemic peroxisome proliferators, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio-(N-beta-hydroxyethyl)ac etamide and di(2-ethylhexyl)phthalate. Carcinogenesis. 1988 Jan;9(1):167-9. doi: 10.1093/carcin/9.1.167. PMID: 3257172.
10: Ohmura T, Ledda-Columbano GM, Piga R, Columbano A, Glemba J, Katyal SL, Locker J, Shinozuka H. Hepatocyte proliferation induced by a single dose of a peroxisome proliferator. Am J Pathol. 1996 Mar;148(3):815-24. PMID: 8774136; PMCID: PMC1861716.
